Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments Waiver by Application Studies; Draft Guidance for Industry and Food and Drug Administration Staff; Availability, 56610-56612 [2017-25774]
Download as PDF
56610
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
pmangrum on DSK3GDR082PROD with NOTICES1
medical device, food additive, or color
additive) was subject to regulatory
review by FDA before the item was
marketed. Under these acts, a product’s
regulatory review period forms the basis
for determining the amount of extension
an applicant may receive.
A regulatory review period consists of
two periods of time: a testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of USPTO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product VELTASSA
(patiromer sorbitex calcium).
VELTASSA is indicated for the
treatment of hyperkalemia. Subsequent
to this approval, the USPTO received a
patent term restoration application for
VELTASSA (U.S. Patent No. 8,147,873)
from Relypsa, Inc., and the USPTO
requested FDA’s assistance in
determining this patent’s eligibility for
patent term restoration. In a letter dated
September 1, 2016, FDA advised the
USPTO that this human drug product
had undergone a regulatory review
period and that the approval of
VELTASSA represented the first
permitted commercial marketing or use
of the product. Thereafter, the USPTO
requested that FDA determine the
product’s regulatory review period.
II. Determination of Regulatory Review
Period
FDA has determined that the
applicable regulatory review period for
VELTASSA is 2,844 days. Of this time,
2,478 days occurred during the testing
phase of the regulatory review period,
while 366 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 355(i)) became effective: January
9, 2008. FDA has verified the
applicant’s claim that January 9, 2008,
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
is the date the investigational new drug
application (IND) became effective.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the FD&C Act: October 21,
2014. FDA has verified the applicant’s
claim that the new drug application
(NDA) for VELTASSA (NDA 205739)
was initially submitted on October 21,
2014.
3. The date the application was
approved: October 21, 2015. FDA has
verified the applicant’s claim that NDA
205739 was approved on October 21,
2015.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the USPTO applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 832 days of patent
term extension.
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of
§ 60.30, including but not limited to:
Must be timely (see DATES), must be
filed in accordance with § 10.20, must
contain sufficient facts to merit an FDA
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: November 24, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–25761 Filed 11–28–17; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–D–5625]
Recommendations for Dual 510(k) and
Clinical Laboratory Improvement
Amendments Waiver by Application
Studies; Draft Guidance for Industry
and Food and Drug Administration
Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the draft
guidance entitled ‘‘Recommendations
for Dual 510(k) and Clinical Laboratory
Improvement Amendments (CLIA)
Waiver by Application Studies.’’ It
describes study designs for generating
data that supports both 510(k) clearance
and CLIA waived categorization. Use of
the Dual 510(k) and CLIA Waiver by
Application pathway is optional;
however, FDA believes this pathway is
in many instances the least burdensome
and fastest approach for manufacturers
to obtain a CLIA waived categorization
in addition to 510(k) clearance for new
In Vitro Diagnostic (IVD) devices. FDA
believes increased use of this pathway
will speed up the process of bringing
simple and accurate IVD devices to
CLIA waived settings, which will better
serve patients and providers. This draft
guidance is not final nor is it in effect
at this time.
DATES: Submit either electronic or
written comments on the draft guidance
by January 29, 2018 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
E:\FR\FM\29NON1.SGM
29NON1
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
pmangrum on DSK3GDR082PROD with NOTICES1
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–D–5625 for ‘‘Recommendations
for Dual 510(k) and CLIA Waiver by
Application Studies.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR–2015–09–18/pdf/2015–
23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21CFR
10.115(g)(5)).
An electronic copy of the guidance
document is available for download
from the internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the draft guidance
document entitled ‘‘Recommendations
for Dual 510(k) and CLIA Waiver by
Application Studies’’ to the Office of the
Center Director, Guidance and Policy
Development, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
FOR FURTHER INFORMATION CONTACT:
Peter Tobin, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5645, Silver Spring,
MD 20993–0002, 240–402–6169.
SUPPLEMENTARY INFORMATION:
I. Background
In an application for CLIA waived
categorization (CLIA Waiver by
Application) a manufacturer submits
evidence to FDA that a test, initially
categorized as moderate complexity,
meets the CLIA statutory criteria for
waiver, 42 U.S.C. 263a(d)(3), and
requests that FDA categorize the test as
waived. Historically, CLIA Waiver by
Application has followed clearance or
approval of an IVD test. This stepwise
approach currently remains the most
utilized path by manufacturers. For
additional information, please see
FDA’s Guidance, ‘‘Administrative
Procedures for CLIA Categorization’’
(https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/UCM070889).
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
56611
While a premarket notification
(510(k)) and CLIA Waiver by
Application each include discrete
elements not required in the other, both
submissions include comparison and
reproducibility studies. For a 510(k),
such studies are often performed by
trained operators (i.e., laboratory
professionals who meet the
qualifications to perform moderate
complexity testing and with previous
training in performing the test;
sometimes referred to as ‘‘moderate
complexity users’’). For a CLIA Waiver
by Application, such studies must be
conducted by untrained operators (i.e.,
operators in waived settings with
limited or no training or hands on
experience in conducting laboratory
testing; sometimes referred to as
‘‘waived users’’).
An applicant may choose to conduct
a single set of comparison and
reproducibility studies with untrained
operators to satisfy associated
requirements for both 510(k) and CLIA
Waiver by Application. To streamline
the review of such data, the Dual 510(k)
and CLIA Waiver by Application (Dual
Submission) pathway, was established
as part of the Medical Device User Fee
Amendments of 2012 (MDUFA III),
allowing the review of both a 510(k) and
CLIA Waiver Application within a
single submission with a reduced
overall review time.
This guidance leverages FDA’s
experience implementing this pathway
in MDUFA III in order to make the Dual
Submission pathway least burdensome.
Use of this guidance is expected to
reduce study-related costs and provide
time savings for manufacturers of
certain Class II IVD devices intended for
CLIA waived settings.
II. Significance of Guidance
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on Recommendations for Dual 510(k)
and CLIA Waiver by Application
Studies. It does not establish any rights
for any person and is not binding on
FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations. This guidance is not
subject to Executive Order 12866.
III. Electronic Access
Persons interested in obtaining a copy
of the draft guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
E:\FR\FM\29NON1.SGM
29NON1
56612
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Recommendations for Dual 510(k)
and CLIA Waiver by Application
Studies’’ may send an email request to
CDRH-Guidance@fda.hhs.gov to receive
an electronic copy of the document.
Please use the document number 16038
to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance also refers to
previously approved collections of
information found in FDA regulations.
The collections of information in 21
CFR 54 have been approved under
0910–0396; the collections of
information in 21 CFR parts 50 and 56
have been approved under OMB control
number 0910–0755, the collections of
information in 21 CFR 807 have been
approved under 0910–0120; the
collections of information in the
guidance document entitled
‘‘Recommendations for Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) Waiver Applications for
Manufacturers of In Vitro Diagnostic
Devices’’ have been approved under
0910–0598, the collections of
information in the guidance document
entitled ‘‘Requests for Feedback on
Medical Device Submissions’’ have been
approved under 0910–0756; and the
collections of information in the
guidance document entitled
‘‘Administrative Procedures for Clinical
Laboratory Improvement Amendments
of 1988 Categorization’’ have been
approved under 0910–0607.
Dated: November 22, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–25774 Filed 11–28–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
pmangrum on DSK3GDR082PROD with NOTICES1
[Docket No. FDA–2016–E–1292]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; REXULTI
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
SUMMARY:
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
for REXULTI and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
DATES: Anyone with knowledge that any
of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by January 29, 2018.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
May 29, 2018. See ‘‘Petitions’’ in the
SUPPLEMENTARY INFORMATION section for
more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before January 29,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of January 29, 2018.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–E–1292 for ’’Determination of
Regulatory Review Period for Purposes
of Patent Extension; REXULTI.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with § 10.20 (21
CFR 10.20) and other applicable
disclosure law. For more information
about FDA’s posting of comments to
public dockets, see 80 FR 56469,
September 18, 2015, or access the
information at: https://www.gpo.gov/
E:\FR\FM\29NON1.SGM
29NON1
Agencies
[Federal Register Volume 82, Number 228 (Wednesday, November 29, 2017)]
[Notices]
[Pages 56610-56612]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25774]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-D-5625]
Recommendations for Dual 510(k) and Clinical Laboratory
Improvement Amendments Waiver by Application Studies; Draft Guidance
for Industry and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the draft guidance entitled ``Recommendations for
Dual 510(k) and Clinical Laboratory Improvement Amendments (CLIA)
Waiver by Application Studies.'' It describes study designs for
generating data that supports both 510(k) clearance and CLIA waived
categorization. Use of the Dual 510(k) and CLIA Waiver by Application
pathway is optional; however, FDA believes this pathway is in many
instances the least burdensome and fastest approach for manufacturers
to obtain a CLIA waived categorization in addition to 510(k) clearance
for new In Vitro Diagnostic (IVD) devices. FDA believes increased use
of this pathway will speed up the process of bringing simple and
accurate IVD devices to CLIA waived settings, which will better serve
patients and providers. This draft guidance is not final nor is it in
effect at this time.
DATES: Submit either electronic or written comments on the draft
guidance by January 29, 2018 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.
ADDRESSES: You may submit comments on any guidance at any time as
follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such
[[Page 56611]]
as a manufacturing process. Please note that if you include your name,
contact information, or other information that identifies you in the
body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-D-5625 for ``Recommendations for Dual 510(k) and CLIA Waiver
by Application Studies.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21CFR
10.115(g)(5)).
An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the draft guidance document entitled
``Recommendations for Dual 510(k) and CLIA Waiver by Application
Studies'' to the Office of the Center Director, Guidance and Policy
Development, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist
that office in processing your request.
FOR FURTHER INFORMATION CONTACT: Peter Tobin, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5645, Silver Spring, MD 20993-0002, 240-402-6169.
SUPPLEMENTARY INFORMATION:
I. Background
In an application for CLIA waived categorization (CLIA Waiver by
Application) a manufacturer submits evidence to FDA that a test,
initially categorized as moderate complexity, meets the CLIA statutory
criteria for waiver, 42 U.S.C. 263a(d)(3), and requests that FDA
categorize the test as waived. Historically, CLIA Waiver by Application
has followed clearance or approval of an IVD test. This stepwise
approach currently remains the most utilized path by manufacturers. For
additional information, please see FDA's Guidance, ``Administrative
Procedures for CLIA Categorization'' (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM070889).
While a premarket notification (510(k)) and CLIA Waiver by
Application each include discrete elements not required in the other,
both submissions include comparison and reproducibility studies. For a
510(k), such studies are often performed by trained operators (i.e.,
laboratory professionals who meet the qualifications to perform
moderate complexity testing and with previous training in performing
the test; sometimes referred to as ``moderate complexity users''). For
a CLIA Waiver by Application, such studies must be conducted by
untrained operators (i.e., operators in waived settings with limited or
no training or hands on experience in conducting laboratory testing;
sometimes referred to as ``waived users'').
An applicant may choose to conduct a single set of comparison and
reproducibility studies with untrained operators to satisfy associated
requirements for both 510(k) and CLIA Waiver by Application. To
streamline the review of such data, the Dual 510(k) and CLIA Waiver by
Application (Dual Submission) pathway, was established as part of the
Medical Device User Fee Amendments of 2012 (MDUFA III), allowing the
review of both a 510(k) and CLIA Waiver Application within a single
submission with a reduced overall review time.
This guidance leverages FDA's experience implementing this pathway
in MDUFA III in order to make the Dual Submission pathway least
burdensome. Use of this guidance is expected to reduce study-related
costs and provide time savings for manufacturers of certain Class II
IVD devices intended for CLIA waived settings.
II. Significance of Guidance
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on
Recommendations for Dual 510(k) and CLIA Waiver by Application Studies.
It does not establish any rights for any person and is not binding on
FDA or the public. You can use an alternative approach if it satisfies
the requirements of the applicable statutes and regulations. This
guidance is not subject to Executive Order 12866.
III. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by downloading an electronic copy from the Internet. A search
capability for all Center for Devices and Radiological Health guidance
documents is available
[[Page 56612]]
at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance documents are also available at
https://www.regulations.gov. Persons unable to download an electronic
copy of ``Recommendations for Dual 510(k) and CLIA Waiver by
Application Studies'' may send an email request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of the document.
Please use the document number 16038 to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance also refers to previously approved collections
of information found in FDA regulations. The collections of information
in 21 CFR 54 have been approved under 0910-0396; the collections of
information in 21 CFR parts 50 and 56 have been approved under OMB
control number 0910-0755, the collections of information in 21 CFR 807
have been approved under 0910-0120; the collections of information in
the guidance document entitled ``Recommendations for Clinical
Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications
for Manufacturers of In Vitro Diagnostic Devices'' have been approved
under 0910-0598, the collections of information in the guidance
document entitled ``Requests for Feedback on Medical Device
Submissions'' have been approved under 0910-0756; and the collections
of information in the guidance document entitled ``Administrative
Procedures for Clinical Laboratory Improvement Amendments of 1988
Categorization'' have been approved under 0910-0607.
Dated: November 22, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-25774 Filed 11-28-17; 8:45 am]
BILLING CODE 4164-01-P